Starpharma Announces License Agreement with Genentech
Released
Released
Announcement PDF
ASX Announcement
Starpharma Announces a Collaboration and License
Agreement with Genentech to Develop Innovative
DEP® Cancer Therapies
●
Starpharma will employ its proprietary DEP® platform technology to develop dendrimerdrug conjugates that incorporate Genentech medicines for certain oncology targets.
●
Starpharma will commence development activities immediately and work exclusively
with Genentech in relation to those targets.
●
Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million), and
is eligible for development, commercial and net sales milestones up to USD $564 million
(~AUD $855 million), as well as tiered royalties on global net sales.
Melbourne, Australia; 22 September 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an
innovative biotechnology company with two decades of experience in advancing dendrimer
technology from the lab to the patient, today announces the signing of a collaboration and license
agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies
that leverage Starpharma’s proprietary DEP® drug delivery technology.
“We are excited to enter into this agreement, which recognises Starpharma’s dendrimer
technology and its potential to benefit novel drug development. It also reflects the diligent work
undertaken during the past three years by Starpharma and Genentech of our previous
collaborative research focused on innovating and developing cancer therapies utilising
Starpharma’s proprietary dendrimer technology platform, DEP®,” said Cheryl Maley, CEO of
Starpharma. “Genentech’s world-class scientific expertise makes them an ideal collaborator, and
we look forward to working together to improve patient outcomes and realise the advantages
presented by Starpharma’s DEP® technology platform.”
Terms of the Agreement
●
Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million) and
is eligible to receive up to USD $564 million (~AUD $855 million) in success-based
development, regulatory, and commercial milestones. In addition to this amount,
Starpharma is eligible for tiered royalties on global net sales of products resulting from the
collaboration.
●
All contracted financial terms are denominated in US dollars.
●
Starpharma will employ its proprietary DEP® platform technology to generate dendrimerdrug conjugates that incorporate Genentech medicines directed to selected oncology
targets.
●
Starpharma will not be permitted to generate products directed to these selected
oncology targets for itself or third parties.
●
Starpharma has granted Genentech an exclusive worldwide license under Starpharma’s
IP to commercialize products resulting from the parties’ collaboration.
●
Genentech will be responsible for all development and commercialization of products
resulting from the collaboration, which could include multiple products for each target.
“Building on three years of collaborative research, we are confident the shared commitment and
strengths of both teams will enable effective execution, with the overarching goal of delivering
meaningful outcomes for patients,” said Cheryl Maley.
“For more than 60 years, we have been developing innovative oncology medicines, and our
dedication to transforming cancer care remains unwavering," said Boris L. Zaïtra, Head of Roche
Corporate Business Development. "We're committed to turning science into life-changing
breakthroughs for patients.”
Cheryl Maley added, “A key strategic priority for Starpharma is to build new, high-impact
partnerships that unlock the full potential of our DEP® platform. By actively pursuing licensing
opportunities and collaborating with leading organisations, we aim to expand market reach and
enable our partners to deliver significantly improved therapies to patients worldwide.”
Starpharma’s DEP® platform technology offers significant benefits in drug development, including
improved solubility, increased efficacy, pharmacokinetic control, and improved toxicity profiles.
These advantages can be applied to a wide range of drug classes, such as small molecules,
peptides, and proteins, as well as to the development of chemotherapeutics, radiotheranostics,
and antibody-drug conjugates. These benefits provide companies with opportunities to enhance
product attributes by differentiating their portfolios and unlocking additional treatment
indications.
Visit Starpharma’s new Investor Hub to access the latest company
developments, updates, and strategic insights, and submit questions. By
joining our Investor Hub, you will gain access to commentary from CEO
Cheryl Maley and resources designed to help you stay connected with
Starpharma’s story.
Scan the QR code or visit: https://investors.starpharma.com/link/yaGK6r
2
About Starpharma
Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in
advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses,
such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer
technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their
size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and
pharmaceutical applications.
Starpharma’s portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product)
assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-thecounter (OTC) products.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
WE Communications
Hannah Howlett
+61 450 648 064
WE-AUStarPharma@weworldwide.com
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, Chief Financial and Operations Officer
and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the
Chair, Mr Rob Thomas.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of
forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”,
“estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could
be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or
potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause actual results to be materially different from any future results, performance or achievements expressed
or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other
authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates
will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular,
management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among
other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or
delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection;
competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks
and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this
document and does not assume any obligation to update any forward-looking statements contained in this document as a result of
new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this
document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or
warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this
document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee
as to the past, present or the future performance of any Starpharma product.
3
Share your feedback
Discover